{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:17Z","timestamp":1740106997356,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00520-022-07341-7","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T12:05:46Z","timestamp":1661947546000},"page":"9191-9201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-8480","authenticated-orcid":false,"given":"Sigal","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana Ilic","family":"Bogojevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Rainville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"issue":"1","key":"7341_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"issue":"1","key":"7341_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3747\/co.2008.198","volume":"15","author":"CT Kouroukis","year":"2008","unstructured":"Kouroukis CT, Chia S, Verma S, Robson D, Desbiens C, Cripps C, Mikhael J (2008) Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol 15(1):9\u201323. https:\/\/doi.org\/10.3747\/co.2008.198","journal-title":"Curr Oncol"},{"issue":"19","key":"7341_CR3","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/jco.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187\u20133205. https:\/\/doi.org\/10.1200\/jco.2006.06.4451","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"7341_CR4","doi-asserted-by":"publisher","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol 21(Suppl 5):v248-251. https:\/\/doi.org\/10.1093\/annonc\/mdq195","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"7341_CR5","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27(suppl 5):v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"issue":"4","key":"7341_CR6","first-page":"228","volume":"43","author":"AJ Lucas","year":"2018","unstructured":"Lucas AJ, Olin JL, Coleman MD (2018) Management and preventive measures for febrile neutropenia. P T 43(4):228\u2013232","journal-title":"P T"},{"issue":"28","key":"7341_CR7","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/jco.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/jco.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"7341_CR8","unstructured":"Amgen Ltd, UK Neupogen (filgrastim) Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/608\/smpc#INDICATIONS. Accessed 2 April 2021"},{"issue":"2","key":"7341_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1537-2995.2006.00699.x","volume":"46","author":"I Bruns","year":"2006","unstructured":"Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, H\u00fcbel K, Haas R, Kobbe G (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion (Paris) 46(2):180\u2013185. https:\/\/doi.org\/10.1111\/j.1537-2995.2006.00699.x","journal-title":"Transfusion (Paris)"},{"issue":"12","key":"7341_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/sj.bmt.1705675","volume":"39","author":"S Fruehauf","year":"2007","unstructured":"Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, Seeger T, Zeller LW, Moehler T, Ho AD, Goldschmidt H (2007) Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 39(12):743\u2013750. https:\/\/doi.org\/10.1038\/sj.bmt.1705675","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"7341_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/j.1537-2995.2006.00911.x","volume":"46","author":"F Kroschinsky","year":"2006","unstructured":"Kroschinsky F, H\u00f6lig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, Oelschlaegel U, Schaich M, H\u00e4nel M, Bornh\u00e4user M, Ehninger G (2006) Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion (Paris) 46(8):1417\u20131423. https:\/\/doi.org\/10.1111\/j.1537-2995.2006.00911.x","journal-title":"Transfusion (Paris)"},{"key":"7341_CR12","unstructured":"Teva Pharma BV, UK Lonquex (lipegfilgrastim) Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/5422\/smpc#INDICATIONS. Accessed 2 April 2021"},{"key":"7341_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/1471-2407-13-386","volume":"13","author":"I Bondarenko","year":"2013","unstructured":"Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P (2013) Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy. BMC Cancer 13:386. https:\/\/doi.org\/10.1186\/1471-2407-13-386","journal-title":"BMC Cancer"},{"issue":"1","key":"7341_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00520-015-2803-9","volume":"24","author":"OA Gladkov","year":"2016","unstructured":"Gladkov OA, Buchner A, Bias P, M\u00fcller U, Els\u00e4sser R (2016) Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study. Support Care Cancer 24(1):395\u2013400. https:\/\/doi.org\/10.1007\/s00520-015-2803-9","journal-title":"Support Care Cancer"},{"issue":"5","key":"7341_CR15","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-020-05711-7","volume":"29","author":"H Link","year":"2021","unstructured":"Link H, Illerhaus G, Martens UM, Salar A, Depenbusch R, K\u00f6hler A, Engelhardt M, Mahlmann S, Zaiss M, Lammerich A, Bias P, Buchner A (2021) Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer 29(5):2519\u20132527. https:\/\/doi.org\/10.1007\/s00520-020-05711-7","journal-title":"Support Care Cancer"},{"key":"7341_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40064-015-1067-7","volume":"4","author":"C Volovat","year":"2015","unstructured":"Volovat C, Bondarenko IM, Gladkov OA, Els\u00e4sser R, Buchner A, Bias P, M\u00fcller U (2015) Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. Springer Plus 4:316. https:\/\/doi.org\/10.1186\/s40064-015-1067-7","journal-title":"Springer Plus"},{"issue":"6","key":"7341_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1078155217714859","volume":"24","author":"TC Bond","year":"2018","unstructured":"Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B (2018) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract 24(6):412\u2013423. https:\/\/doi.org\/10.1177\/1078155217714859","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"7341_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00520-015-2777-7","volume":"24","author":"IM Bondarenko","year":"2016","unstructured":"Bondarenko IM, Bias P, Buchner A (2016) Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Support Care Cancer 24(1):267\u2013273. https:\/\/doi.org\/10.1007\/s00520-015-2777-7","journal-title":"Support Care Cancer"},{"issue":"7","key":"7341_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/03007995.2018.1560200","volume":"35","author":"T Fietz","year":"2019","unstructured":"Fietz T, L\u00fcck A, Schulz H, Harde J, Losem C, Grebhardt S, Wolff T, Potthoff K, M\u00fcller U, Zaiss M, Kurbacher CM (2019) Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR. Curr Med Res Opin 35(7):1127\u20131138. https:\/\/doi.org\/10.1080\/03007995.2018.1560200","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"7341_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/17843286.2019.1646539","volume":"76","author":"C Fontaine","year":"2021","unstructured":"Fontaine C, Claes N, Graas MP, Samani KK, Vuylsteke P, Vulsteke C (2021) Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg. Acta Clin Belg 76(1):10\u201315. https:\/\/doi.org\/10.1080\/17843286.2019.1646539","journal-title":"Acta Clin Belg"},{"issue":"3","key":"7341_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000512594","volume":"44","author":"C Gessner","year":"2021","unstructured":"Gessner C, Potthoff K, Frost N (2021) Efficacy and safety of lipegfilgrastim in lung cancer patients receiving myelosuppressive chemotherapy in a real-world setting: results of an analysis of pooled data from two non-interventional european studies. Oncol Res Treat 44(3):93\u2013102. https:\/\/doi.org\/10.1159\/000512594","journal-title":"Oncol Res Treat"},{"issue":"3","key":"7341_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.21873\/invivo.11059","volume":"31","author":"L Holubec","year":"2017","unstructured":"Holubec L, Polivka J, Lisnerova L, Kubikova T, Safanda M (2017) The effectiveness of febrile neutropenia prophylaxis with lipegfilgrastim in routine clinical practice. In Vivo 31(3):303\u2013306. https:\/\/doi.org\/10.21873\/invivo.11059","journal-title":"In Vivo"},{"key":"7341_CR23","doi-asserted-by":"publisher","first-page":"655355","DOI":"10.3389\/fonc.2021.655355","volume":"11","author":"AS Merseburger","year":"2021","unstructured":"Merseburger AS, Geiges G, Klier J, Wiesholzer M, Pichler P (2021) Pooled analysis on the effectiveness and safety of lipegfilgrastim in patients with urological malignancies in the real-world setting. Front Oncol 11:655355. https:\/\/doi.org\/10.3389\/fonc.2021.655355","journal-title":"Front Oncol"},{"issue":"2","key":"7341_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00520-014-2459-x","volume":"23","author":"S Cortes de Miguel","year":"2015","unstructured":"Cortes de Miguel S, Calleja-Hernandez MA, Menjon-Beltran S, Vallejo-Rodriguez I (2015) Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. Support Care Cancer 23(2):547\u2013559. https:\/\/doi.org\/10.1007\/s00520-014-2459-x","journal-title":"Support Care Cancer"},{"issue":"3","key":"7341_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cyto.2008.03.002","volume":"42","author":"AD Panopoulos","year":"2008","unstructured":"Panopoulos AD, Watowich SS (2008) Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and \u2018emergency\u2019 hematopoiesis. Cytokine 42(3):277\u2013288. https:\/\/doi.org\/10.1016\/j.cyto.2008.03.002","journal-title":"Cytokine"},{"issue":"6","key":"7341_CR26","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1517\/14656566.2011.541155","volume":"12","author":"E Saloustros","year":"2011","unstructured":"Saloustros E, Tryfonidis K, Georgoulias V (2011) Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Expert Opin Pharmacother 12(6):851\u2013863. https:\/\/doi.org\/10.1517\/14656566.2011.541155","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 2","key":"7341_CR27","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1517\/14728222.2011.652089","volume":"16","author":"N Silvestris","year":"2012","unstructured":"Silvestris N, Del Re M, Azzariti A, Maiello E, Lombardi L, Cinieri S, Guarini A, Brunetti AE, Delcuratolo S, De Vita F, Pisconti S, Danesi R, Colucci G (2012) Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opin Ther Targets 16(Suppl 2):S111-117. https:\/\/doi.org\/10.1517\/14728222.2011.652089","journal-title":"Expert Opin Ther Targets"},{"key":"7341_CR28","unstructured":"European Medicines Agency (EMA). Committee for medicinal products for human use (CHMP) assessment report: Lonquex. 30 May 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002556\/WC500148382.pdf. Accessed 18 July 2018"},{"issue":"1","key":"7341_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/21556660.2019.1604376","volume":"8","author":"S Kaplan","year":"2019","unstructured":"Kaplan S, Lang N, Gasparic M, Rainville C, Haralabopoulos G, Borroni E (2019) Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe. J Drug Assess 8(1):70\u201376. https:\/\/doi.org\/10.1080\/21556660.2019.1604376","journal-title":"J Drug Assess"},{"issue":"4","key":"7341_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0300891620927093","volume":"106","author":"AC Tralongo","year":"2020","unstructured":"Tralongo AC, Antonuzzo A, Pronzato P, Sbrana A, Turrini M, Zoratto F, Danova M (2020) Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM). Tumori 106(4):273\u2013280. https:\/\/doi.org\/10.1177\/0300891620927093","journal-title":"Tumori"},{"key":"7341_CR31","doi-asserted-by":"publisher","unstructured":"Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA (2020) NCCN guidelines insights: hematopoietic growth factors, Version 1.2020. J Natl Compr Canc Netw 18(1):12\u201322. https:\/\/doi.org\/10.6004\/jnccn.2020.0002","DOI":"10.6004\/jnccn.2020.0002"},{"issue":"3","key":"7341_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/jop.091094","volume":"6","author":"HA Burris","year":"2010","unstructured":"Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-hodgkin\u2019s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 6(3):133\u2013140. https:\/\/doi.org\/10.1200\/jop.091094","journal-title":"J Oncol Pract"},{"issue":"2","key":"7341_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000229504","volume":"77","author":"DV Skarlos","year":"2009","unstructured":"Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilas G (2009) Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology 77(2):107\u2013112. https:\/\/doi.org\/10.1159\/000229504","journal-title":"Oncology"},{"key":"7341_CR34","doi-asserted-by":"publisher","unstructured":"Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L (2017) Myeloid growth factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(12):1520\u20131541. https:\/\/doi.org\/10.6004\/jnccn.2017.0175","DOI":"10.6004\/jnccn.2017.0175"},{"issue":"9","key":"7341_CR35","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00520-020-05295-2","volume":"28","author":"PL Gawade","year":"2020","unstructured":"Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, Bradbury BD (2020) Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 28(9):4413\u20134424. https:\/\/doi.org\/10.1007\/s00520-020-05295-2","journal-title":"Support Care Cancer"},{"issue":"9","key":"7341_CR36","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1200\/jco.2012.42.7252","volume":"31","author":"RM Conti","year":"2013","unstructured":"Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB (2013) Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 31(9):1134\u20131139. https:\/\/doi.org\/10.1200\/jco.2012.42.7252","journal-title":"J Clin Oncol"},{"issue":"1","key":"7341_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.6004\/jnccn.2016.0007","volume":"14","author":"AA Eaton","year":"2016","unstructured":"Eaton AA, Sima CS, Panageas KS (2016) Prevalence and safety of off-label use of chemotherapeutic agents in older patients with breast cancer: estimates from SEER-medicare data. J Natl Compr Canc Netw 14(1):57\u201365","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"7341_CR38","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/clpt.2012.30","volume":"91","author":"J Morris","year":"2012","unstructured":"Morris J (2012) The use of observational health-care data to identify and report on off-label use of biopharmaceutical products. Clin Pharmacol Ther 91(5):937\u2013942. https:\/\/doi.org\/10.1038\/clpt.2012.30","journal-title":"Clin Pharmacol Ther"},{"key":"7341_CR39","unstructured":"European Commission, Directorate-General for Health, Food Safety, Marjolein W, Lisman J, Hoebert J, Molt\u00f3 Puigmarti C, Dijk L, Langedijk J, Marchange S, Damen N, Vervloet M (2019) Study on off-label use of medicinal products in the European Union: report. Publications Office."},{"issue":"3","key":"7341_CR40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40258-014-0087-8","volume":"12","author":"F Bocquet","year":"2014","unstructured":"Bocquet F, Paubel P, Fusier I, Cordonnier AL, Le Pen C, Sin\u00e8gre M (2014) Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis. Appl Health Econ Health Policy 12(3):315\u2013326. https:\/\/doi.org\/10.1007\/s40258-014-0087-8","journal-title":"Appl Health Econ Health Policy"},{"key":"7341_CR41","unstructured":"Nordic MDS Group. Guidelines for the diagnosis and treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia, 8th update, May 2017. https:\/\/www.nmds.org\/attachments\/article\/92\/Guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20MDS%20and%20CMML_17.pdf. Accessed April 2 2021"},{"issue":"6","key":"7341_CR42","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/cam4.344","volume":"3","author":"G Barnes","year":"2014","unstructured":"Barnes G, Pathak A, Schwartzberg L (2014) G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med 3(6):1477\u20131484. https:\/\/doi.org\/10.1002\/cam4.344","journal-title":"Cancer Med"},{"issue":"1","key":"7341_CR43","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s13187-019-01638-8","volume":"35","author":"A Hawkins","year":"2020","unstructured":"Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA (2020) A survey of oncologists\u2019 perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Educ 35(1):178\u2013186. https:\/\/doi.org\/10.1007\/s13187-019-01638-8","journal-title":"J Cancer Educ"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07341-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07341-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07341-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T10:41:41Z","timestamp":1667472101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07341-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7341"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07341-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and a waiver for patient informed consent were obtained for all participating centers. The study was performed in accordance with local ethics committees and regulatory requirements in participating countries.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Teva Pharmaceutical Industries Ltd (and\/or its affiliates). The sponsor had a role in study design, analysis and interpretation of data, and manuscript writing.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The sponsor had a role in the design and conduct of the study; study supervision, management, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the sponsor"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect those of Teva Pharmaceutical Industries Ltd and\/or its affiliates.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}